The younger the child is, the more active the growth and differentiation of the cartilage layer of the epiphysis, the more space and potential the child has for growth, the more sensitive the child is to treatment, and the better the effect of medication for growth promotion; on the other hand, the treatment cost of short stature is proportional to the weight of the patient, the heavier the child is, the higher the dose of medication, and the higher the treatment cost. The heavier the weight of the child, the higher the dosage of medication and the higher the cost of treatment. Generally speaking, the age of choosing treatment for short stature differs slightly from one cause to another. For children with growth hormone deficiency, treatment is usually started at the age of 4-6 years; for idiopathic dwarfism, rhGH treatment is recommended to be started at the age of 5 years; for children younger than fetal age, treatment is recommended to be started at the age of ≥4 years when their height is still lower than the average height of normal children of the same age and sex-2SD; for children with Turner syndrome, rhGH treatment can be started when their height is below the 5th percentile of the growth curve of normal girls, and can be started as early as 2 years old. It can be started as early as 2 years of age. Bone age determines the growth potential of the human body. The younger the bone age, the more space is left for treatment and the more height growth can be obtained, while the older the bone age, the more epiphyseal closure is lost to treatment.